Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eclosion Emerges to Fill A Swiss Start-Up Void

This article was originally published in Start Up

Executive Summary

Despite being home to renowned research institutions and universities and mid- to large-size biopharma companies, Geneva, Switzerland, midway through the last decade, still lacked what it considered a vibrant life sciences start-up scene. A few years later and the Swiss region’s all-hands-on deck approach to building one has birthed a new hybrid model, the public/private endeavor Eclosion, which is one part early-stage incubator and another part venture fund.

You may also be interested in...



Red Script Ventures : Another addition to Johnson & Johnson's early stage R&D tool-box

Red Script is a business accelerator whose purpose is to make early stage investments--either seed or Series A-- in companies developing riskier, but potentially transformative-types of science, such as regenerative medicine or neurostimulation.

Corporate Biotech Incubators

Corporate incubators at Pfizer and Biogen--designed to provide a supply of strategically aligned biotech assets to the parent pipeline--remain unproven. But they're among a range of experiments aimed at helping seed discovery-stage ventures

Hijacking The Messenger

Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities. 

Topics

Related Companies

UsernamePublicRestriction

Register

SC091952

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel